EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain

Antonio Calles, Mirian Alonso, Paloma Martín-Martorell, Ana Gómez, Javier de Castro, Maite Martínez-Aguillo, Anna Estival, Joaquin Mosquera, Natividad Martínez-Banaclocha, Margarita Majem, Roxana Reyes, Eider Azkona und 21 weitere

Cancer Treatment and Research Communications · 2025

DOI: 10.1016/j.ctarc.2025.100905 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Antonio Calles und 32 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Electronic address: antonio.calles@live.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Aminopyridines, Anaplastic Lymphoma Kinase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lorlatinib, a third-generation tyrosine kinase inhibitor (TKI), targets both ALK and ROS1 rearrangements in non-small cell lung cancer (NSCLC). It is approved for ALK-positive patients after progression on prior TKIs but lacks FDA or EMA approval for ROS1-positive NSCLC. This study evaluates lorlatinib's efficacy and safety in both ALK- and ROS1-positive patients through a compassionate use program in Spain. METHODS: We analyzed ALK-positive patients treated from November 2016 to February 2019 and ROS1-positive patients treated from November 2016 to March 2021. Eligible patients had Stage IV NSCLC with confirmed ALK or ROS1 rearrangements and prior TKI therapy. For ALK-positive patients, at least two prior TKIs were required if crizotinib was used first. For ROS1-positive patients, prior crizotinib was required. RESULTS: In 61 ALK-positive patients, 59 % had brain metastasis, and 85.2 % received at least two prior ALK TKIs. The overall response rate (ORR) was 32.8 %, with a median progression-free survival (PFS) of 11.2 months. Intracranial ORR was 47.6 %, with higher efficacy in patients with evaluable brain metastasis. In patients with 1, 2, or ≥3 lines of previous TKIs, we observed a median PFS of 15.1, 11.1 and 7.6 months, respectively. Among 42 ROS1-positive patients, 59 % had brain metastasis, and 61.9 % received ≥2 prior therapies. The confirmed ORR was 47.6 %, with 16.7 % complete responses. Median PFS was 10 months. Patients receiving crizotinib alone had a median PFS of 10 months, while those with two prior TKIs had a median PFS of 8.5 months. Intracranial response was 44.4 %, rising to 57.1 % in patients evaluable with brain metastasis. No new safety signals were observed. CONCLUSION: Lorlatinib demonstrated consistent efficacy and manageable safety in both ALK- and ROS1-positive NSCLC patients treated under the compassionate use program in Spain. These real-world findings support its use as an effective treatment option in heavily pretreated patients. MICROABSTRACT: We evaluated the efficacy and safety of lorlatinib in ALK- and ROS1-positive NSCLC patients within a compassionate use program in Spain. Among 61 ALK-positive patients, including 59 % with brain metastasis and 85.2 % treated with at least 2 prior ALK TKIs, lorlatinib achieved a confirmed overall response rate (ORR) of 32.8 % and a median progression-free survival (PFS) of 11.2 months. In 42 ROS1-positive patients previously treated with crizotinib, lorlatinib showed an ORR of 47.6 % and a median PFS of 10 months, confirming its clinical activity despite the lack of FDA or EMA approval for this indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAminopyridinesAnaplastic Lymphoma KinaseProto-Oncogene ProteinsLactamsProtein-Tyrosine KinasesLactams, MacrocyclicProtein Kinase InhibitorsHumansMaleFemaleMiddle AgedCompassionate Use TrialsAgedSpainAdultGene RearrangementPyrazolesAged, 80 and over

Stichwörter der Autor:innen

ALKAnaplastic lymphoma kinaseBrain metastasisLorlatinibNon-small-cell lung cancerROS1Targeted therapyTyrosine-kinase inhibitor

Substanzen

lorlatinibROS1 protein, humanAminopyridinesAnaplastic Lymphoma KinaseProto-Oncogene ProteinsALK protein, humanLactamsProtein-Tyrosine KinasesLactams, MacrocyclicProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Electronic address: antonio.calles@live.com.
  • Medical Oncology Department, Hospital Virgen del Rocío, Sevilla, Spain.
  • Medical Oncology Department, H. Clínico Universitario de Valencia, Spain.
  • Medical Oncology Department, H. Ramón y Cajal, Madrid, Spain.
  • Medical Oncology Department, H. La Paz, Madrid, Spain.
  • Medical Oncology Department, C.H. Navarra, Pamplona, Spain.

Förderung

  • Pfizer

Zitieren

APA

Calles, A., Alonso, M., Martín-Martorell, P., Gómez, A., de Castro, J., Martínez-Aguillo, M., Estival, A., Mosquera, J., Martínez-Banaclocha, N., Majem, M., Reyes, R., Azkona, E., Ortega, A. L., Aguin, S., Santos, A., Aguilar, A., Cucurull, M., Blasco, A., Calvo, V., …, & Spanish Lung Cancer Group (2025). Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100905

Vancouver

Calles A, Alonso M, Martín-Martorell P, Gómez A, de Castro J, Martínez-Aguillo M, et al. Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100905

BibTeX
@article{Calles2025,
  author = {Calles, Antonio and Alonso, Mirian and Martín-Martorell, Paloma and Gómez, Ana and de Castro, Javier and Martínez-Aguillo, Maite and Estival, Anna and Mosquera, Joaquin and Martínez-Banaclocha, Natividad and Majem, Margarita and Reyes, Roxana and Azkona, Eider and Ortega, Ana Laura and Aguin, Santiago and Santos, Ana and Aguilar, Andrés and Cucurull, Marc and Blasco, Ana and Calvo, Virginia and Isla, Dolores and Nadal, Ernest and Aguado, Carlos and Sais, Elia and Juan-Vidal, Oscar and Diz-Taín, MPilar and Taus, Álvaro and Villanueva, Noemí and Bayona, Cristina and Amenedo, Margarita and Mielgo, Xabier and Arriola, Esperanza and Baena, Javier and Spanish Lung Cancer Group, Spanish Lung Cancer Group},
  title = {Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain},
  journal = {Cancer Treatment and Research Communications},
  year = {2025},
  doi = {10.1016/j.ctarc.2025.100905}
}
Kostenlos starten →